GALECTIN THERAPEUTICS INC.

(GALT)
  Report
Delayed Nasdaq  -  05/23 03:58:49 pm EDT
1.320 USD   +3.13%
05/23Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress
AQ
05/17HC Wainwright Adjusts Price Target on Galectin Therapeutics to $11 From $14, Reiterates Buy Rating
MT
05/16Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

GALECTIN THERAPEUTICS INC : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)

12/21/2021 | 07:53am EDT

Item 1.01 Entry into a Material Definitive Agreement.

On December 20, 2021, Galectin Therapeutics Inc. (the "Company") executed the second promissory note (the "December 2021 Note") with Richard E. Uihlein pursuant to a loan agreement in the aggregate of twenty million dollars ($20,000,000) (the "Loan Agreement") entered in September 2021. The December 2021 Note was delivered to evidence the second loan in the principal amount of ten million dollars.

The December 2021 Note has a maturity date of December 20, 2025 and is convertible into the Company's common stock at a conversion price equal to $5.43 per share at the option of the noteholder, which is 228% of the closing price of our stock on December 17, 2021. The December 2021 Note bears interest at the rate of two percent (2%) per annum, compounded annually, and accrues additional interest at a rate of two and one-half percent (2.5%) per quarter (the "Additional Interest") beginning on the date of issuance of the December 2021 Note and ending on the maturity date; provided however, that such Additional Interest is payable if and only if the noteholder elects to convert the entire balance of the December 2021 Note into the Company's common stock.

The Line of Credit Letter Agreement (the "Line of Credit") for $10 million between the Company and Richard E. Uihlein, dated December 19, 2017, and most recently amended on January 11, 2019, which by its terms would otherwise expire on December 31, 2021, was terminated upon closing of the second $10 million unsecured convertible loan in December 2021. Currently there are no borrowings under the Line of Credit.

The foregoing description of the December 2021 Note does not purport to be complete, and the terms of the December 2021 Note are subject to, and qualified in their entirety by reference to the December 2021 Note, which is filed herewith as Exhibit 10.1 and is incorporated herein by reference.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an

Off-Balance Sheet Arrangement of Registrant.

The information contained in Item 1.01 above is incorporated herein by reference.

Item 3.02 Unregistered Sales of Equity Securities.

The information contained in Item 1.01 above is incorporated herein by reference.

The sale and issuance of the Note as disclosed in Item 1.01 of this Current Report on Form 8-K has been determined to be exempt from registration under the Act in reliance on Section 4(2) of the Act and Rule 506 of Regulation D promulgated under the Act.

                                     - 2 -
--------------------------------------------------------------------------------

Item 8.01 Other Items.


On December 21, 2021, Galectin Therapeutics Inc. (the "Company) issued the press release attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.



Exhibit  No.

  10.1   Unsecured Convertible Promissory Note, dated December 20, 2021
  99.1   Press release, dated December 21, 2021



                                     - 3 -

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about GALECTIN THERAPEUTICS INC.
05/23Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conferen..
AQ
05/17HC Wainwright Adjusts Price Target on Galectin Therapeutics to $11 From $14, Reiterates..
MT
05/16Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 an..
AQ
05/16GALECTIN THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition ..
AQ
05/16Galectin Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 3..
CI
05/16NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
04/14Galectin Therapeutics Says Study of Liver Disease Drug Candidate to Proceed Without Cha..
MT
04/14Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitor..
AQ
04/14Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitor..
CI
04/14GALECTIN THERAPEUTICS : Reports the Positive Outcome of the First Data and Safety Monitori..
PU
More news
Analyst Recommendations on GALECTIN THERAPEUTICS INC.
More recommendations